Cargando…
Peptide Immunotherapy for Type 1 Diabetes—Clinical Advances
Autoimmune and allergic diseases occur when an individual mounts an inappropriate immune response to a self-antigen or an innocuous environmental antigen. This triggers a pathogenic T-cell response resulting in damage to specific tissues and organs. In type 1 diabetes (T1D), this manifests as destru...
Autores principales: | Smith, Emma L., Peakman, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836708/ https://www.ncbi.nlm.nih.gov/pubmed/29541078 http://dx.doi.org/10.3389/fimmu.2018.00392 |
Ejemplares similares
-
Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes
por: Liu, Yuk-Fun, et al.
Publicado: (2022) -
Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential
por: Peakman, Mark, et al.
Publicado: (2010) -
Editorial: 21st century advances in type 1 diabetes research and immunotherapy
por: Bleich, David
Publicado: (2023) -
Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials
por: Arif, Sefina, et al.
Publicado: (2023) -
Reduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide Decline
por: Orban, Tihamer, et al.
Publicado: (2014)